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Background: Vancomycin is effective against gram-positive bacteria and the first-line antibiotic for treatment of
proven coagulase-negative staphylococcal infections. The aim of this study is bipartite: first, to assess the percentage
of therapeutic initial trough serum concentrations and second, to evaluate the adequacy of the therapeutic range
in interrelationship with the observed MIC-values in neonates.
Methods: In this study, preterm and term neonates admitted at a tertiary NICU in the Netherlands from January
2009 to December 2012 and treated with vancomycin for a proven gram-positive infection were included. Trough
serum concentrations were measured prior to administration of the 5th dose. Trough concentrations in the range
of 10 to 15 mg/L were considered therapeutic. Staphylococcal species minimal inhibitory concentrations (MIC’s)
were determined using the E-test method. Species identification was performed by matrix-assisted laser
desorption/ionisation mass spectrometry.
Results: Of the 112 neonates, 53 neonates (47%) had sub-therapeutic initial trough serum concentrations of
vancomycin, whereas 22% had supra-therapeutic initial trough serum concentrations. In all patients doses were
adjusted on basis of the initial trough concentration. In 40% (23/57) of the neonates the second trough concentration
remained sub-therapeutic. MIC’s were determined for 30 coagulase-negative Staphylococcus isolates obtained from 19
patients. Only 4 out of 19 subjects had a trough concentration greater than tenfold the MIC.
Conclusions: Forty-seven percent of the neonates had sub-therapeutic initial trough serum concentrations of
vancomycin. The MIC-data indicate that the percentages of underdosed patients may be greater. It may be advisable
to increase the lower limit of the therapeutic range for European neonates.
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Ongoing improvement in the care of increasingly younger
and critically ill neonates in Neonatal Intensive Care Units
(NICU) coincides with an increased use of indwelling cen-
tral venous catheters (CVC). Neonates are highly suscep-
tible to invasive gram-positive infections associated with
use of these CVCs. Coagulase-negative Staphylococcus
(CNS) and Staphylococcus aureus are the most common* Correspondence: r.mathot@amc.uva.nl
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unless otherwise stated.causative pathogens found in neonatal central line sepsis
[1-3]. Vancomycin is an effective agent against gram-
positive bacteria, especially resistant staphylococci, and is
therefore the first line antibiotic for treatment of proven
coagulase-negative staphylococcal infections [4,5].
Adequate dosing of vancomycin is of major import-
ance as too low or too high plasma concentrations can
lead to ineffective therapy or toxicity, respectively. As a
result, therapeutic drug monitoring (TDM) is applied in
order to optimize vancomycin therapy. Several vanco-
mycin dosage regimens have been proposed for term
and preterm neonates. Most of these dosage regimensl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Vancomycin dosing regimen
Age categories Daily dose Dose frequency
(mg/kg/day) (dose per 24 h)
I < 26 weeks PMA 15 1 dose
II 26 – 37 weeks GA & < 7 days PNA 20 2 doses
III > 37 weeks GA & < 7 days PNA 30 2 doses
IV PNA > 7 days (preterm and term) 40 2 doses
Legend: GA: gestational age, PMA: postmenstrual age, PNA: postnatal age.
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ies suggest regimens based on serum creatinin only or
regimens irrespective of gestational or postconceptional
age [7,8].
An efficacy parameter for adequate vancomycin ther-
apy is currently missing and needed. The ratio of the
area under the serum concentration versus time curve
and the minimal inhibitory concentration (AUC/MIC)
has been suggested as an efficacy parameter. The AUC/
MIC, derived from the pharmacokinetic profile of the
patient, can be used to rationalise dosage regimens for
individual neonatal patients [9]. This option has however
not yet been investigated in the neonatal population. For
monitoring purposes assessment of vancomycin trough
concentrations is more feasible. A vancomycin trough
serum concentration of tenfold the MIC is generally
considered the lower limit for the therapeutic concentra-
tion range. It has been reported that an AUC/MIC of
approximately 400 corresponds to a trough serum
concentration of 8 to 9 mg/L [10].
This study was designed to answer two clinical ques-
tions. First, to assess the percentage of sub-therapeutic
trough serum concentrations in a cohort of both term
and preterm neonates and second, to evaluate the
adequacy of the currently used therapeutic range in
relationship with the observed MIC-values.
Methods
The study population consisted of a cohort of preterm
and term neonates admitted at the tertiary NICU of the
Academic Medical Centre in Amsterdam, The Netherlands,
from January 2009 to December 2012, who were treated
with vancomycin for a proven gram-positive infection.
Patient characteristics were extracted from the clinical and
microbiological database. All neonatal patients receiving
vancomycin therapy were eligible for study inclusion,
regardless of gestational age or birth weight. Exclusion
criterion was either an unavailable vancomycin trough
concentration or no or insufficient documentation on
dosage schedules.
Due to the retrospective nature of this study and
because the subjects and data were unidentifiable from
the reported analyses and data, the institutional medical
ethical committee of the Academic Medical Centre
(Amsterdam, The Netherlands) decided that approval
and informed consent were not needed for this study,
which is in line with the Dutch Medical Research (Human
Subjects) Act.
Vancomycin was administered intravenously and dosed
according to hospital dosing guidelines based on national
pediatric dosing guidelines [11]. The applied dosage regi-
men is shown in Table 1. Trough blood samples were
taken routinely before administration of the fifth vanco-
mycin dose according to hospital protocol. Trough serumconcentrations in the range of 10 to 15 mg/L were consid-
ered therapeutic. The total numbers (and%) of cases with
trough concentrations below and above the therapeutic
range (10 – 15 mg/L) were assessed.
The following patient characteristics were obtained
from the medical records: gender, gestational age (in
weeks), birth weight (in grams), postnatal age (in days)
at start of vancomycin treatment, weight (in grams) at
the time of vancomycin treatment, duration of treatment
(in days), relevant co-medication possibly influencing
drug clearance (ibuprofen or indometacin).
Vancomycin susceptibility was tested for all coagulase-
negative staphylococci isolated from bloodcultures of in-
fants receiving vancomycin between January and December
2012. Vancomycin minimal inhibitory concentrations
(MIC’s) were determined using the E-test method accord-
ing to the manufacturer’s guidelines (Biomérieux, Marcy
l’Etoile, France). If more than one isolate was cultured
from the same patient during the same episode, subse-
quent isolates of the same species were excluded if they
showed an identical susceptibility pattern. Species identifi-
cation was performed by matrix-assisted laser desorption/
ionisation mass spectrometry, using MALDI Biotyper
software v3 (Bruker Daltonik GmbH, Bremen, Germany).
SPSS version 18.0 was used to analyze the data and
describe patient demographics. Bivariate correlation was
investigated between measured trough levels and patient
characteristics. As data were not normally distributed,
Spearman’s rho was calculated.
Results
A total of 116 neonates were included in this study. Four
neonates lacked appropriately documented serum con-
centrations and were therefore excluded from the study.
A remaining total of 112 initial trough serum concentra-
tions were analyzed. The first patient category (post-
menstrual age (PMA) < 26 weeks) included only 1
patient, the second category (gestational age (GA) 26 –
37 & postnatal age (PNA) < 7 days) 2 patients, the third
category (GA > 37 weeks & PNA < 7 days) 4 patients and
the last category (preterm or term, PNA > 7 days) included
105 patients. Subjects in the fourth and most substantial
age category demonstrated a median gestational age of
28 weeks (range 24 – 41 weeks), a median birth weight of
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age at start of the therapy of 14 days (range 3 – 112 days),
and median weight at start of the therapy of 1040 grams
(range 500 – 4310 grams).
Combining all groups, the median initial trough serum
concentration was 10.6 mg/L (range 2.2 – 37.6 mg/L, n =
112). In the fourth group, the median initial trough serum
concentration was 10.5 mg/L (range 2.7 – 37.6 mg/L, n =
105). In all groups, a total of 53 of 112 patients (47%) had
a sub-therapeutic (<10 mg/L) initial trough serum concen-
tration of vancomycin, whereas 22 of 112 patients (20%)
had a supra-therapeutic (>15 mg/L) initial trough serum
concentration (Figure 1).
TDM was performed in all of the 112 patients; doses
were adjusted in order to obtain trough concentrations
in the therapeutic range. During continued therapy a
second trough serum concentration was determined in
57 of 112 patients. Vancomycin therapy was stopped
shortly (within 3 days) after the initial trough serum
concentration in the remaining 55 subjects for varying
reasons (mostly after removal of the infected CVC). In
52 out of 57 patients with a second trough serum concen-
tration the vancomycin dosage was adjusted. Twenty-
three of the 57 neonates (40%) still demonstrated
sub-therapeutic trough concentrations after dose adjust-
ment. Dose adjustment resulted in a median trough
serum concentration of 11.0 mg/L (range 3.1 – 37.7 mg/L,
n = 57).
In the studied population initial trough serum concen-
trations were significantly correlated with the gestational
age (r = −0.250, p = 0.03) and the postmenstrual age atFigure 1 Initial vancomycin serum trough concentration vs postmens
postmenstrual age for 112 neonates. The dashed lines indicate the therape
solid line was obtained by linear regression analysis (Spearman’s rho): r = −the start of the therapy (r = −0.248, p = 0.009). Figure 1
shows the relationship between the initial trough serum
concentrations and PMA of the entire population.
In total, 30 coagulase-negative Staphylococcus isolates
from 19 patients were tested for MIC. Staphylococcal
isolates consisted of 19 S. epidermidis, 9 S. capitis and 2
S. warneri isolates. Of these 30 isolates, 2 (7%) showed
an MIC ≤ 0.5 mg/L, 9 (30%) showed an MIC of 1.5 mg/L,
17 (58%) showed an MIC of 2.0 mg/L and 2 (7%) showed
an MIC of 3.0 mg/L. Tenfold the value of the MIC is con-
sidered the lower limit for therapeutic trough serum con-
centrations. By this definition, only 4 out of 19 (21%)
patients (where the MIC was tested) reached therapeutic
trough concentrations. Two patients had an isolate with a
MIC ≤ 0.5 mg/L, 1 patient showed an isolate with a MIC
of 1.5 mg/L and 1 patient showed an isolate with a MIC
of 2.0. These patients achieved a therapeutic concentra-
tion tenfold the MIC. All were classified in the fourth age
category.
Follow-up blood cultures were available in 14 of the
19 subjects. In 13 of the 14 subjects, follow-up blood
cultures were negative, in follow-up blood cultures of 1
subject the initial CNS species was not found, but a new
micro-organism was isolated.
The mortality in the present study cohort was 18%
(21/112). Of these 21 subjects, 6 neonates died due to
respiratory and circulatory compromise during an episode
of severe clinical sepsis. In 4 of these 6 subjects, CNS was
isolated, while in 2 subjects the causative micro-organism
was not found. In the sub-therapeutic group (mortality
7/21), 3 subjects died due to complications of severetrual age. Initial vancomycin serum trough concentration versus
utic range of vancomycin trough concentration (10 – 15 mg/L). The
0.248, p = 0.009.
Sinkeler et al. BMC Pediatrics 2014, 14:193 Page 4 of 6
http://www.biomedcentral.com/1471-2431/14/193necrotizing enterocolitis (NEC): in 1 patient intensive care
treatment was withdrawn following severe perinatal as-
phyxia and a large cerebral hemorrhage caused demise in
1 other infant. Ongoing neonatal sepsis was the cause of
death in 2 other subjects. Both of these suffered ongoing
CNS sepsis, one in the presence of a large vena cava infer-
ior thrombus.
In the supra-therapeutic group (mortality 4/21) 1 sub-
ject died because of respiratory failure in severe bronch-
opulmonary dysplasia (BPD). Three other subjects died
due to complications of clinical sepsis. One of these
suffered sepsis due to a combined Enterobacter species
and S. epidermis infection.
In the therapeutic group (mortality 10/21), 5 patients
died as a result of NEC, 2 due to multi-organ failure fol-
lowing perinatal asphyxia and 2 due to severe respiratory
and circulatory insufficiency (primary pulmonary hyper-
tension of the neonate, PPHN). One patient died as a
result of an ongoing CNS infection.
Discussion
In the present study, we studied initial trough serum
concentrations of vancomycin in critically ill neonates.
In this study, only about one third of all subjects had
adequate initial trough serum concentrations, indicating
inadequate dosing in the majority of subjects, thus
exposing a large number of subjects to either the risk of
ongoing infection or complications due to vancomycin
toxicity.
There is significant discussion regarding the adequate
range of trough concentrations for successful treatment.
Therapeutic trough vancomycin concentrations range
from 5 mg/L to 25 mg/L [8,12]. Thus, reports on the
number of subjects with sub-therapeutic levels of
vancomycin show wildly varying results, with reported
percentages ranging from 24% to 58% [13,14]. In the
present study, approximately half of the neonates had
initial trough serum concentrations in the sub-therapeutic
range after the administration of the recommended dosing
regimen. Unexpectedly, after TDM, the percentage of
patients with sub-therapeutic serum concentrations
decreased only from an initial 58% to 40% of patients. This
moderate increase in the number of subjects reaching
therapeutic serum concentrations may be hampered by
the significant increase of renal function shortly after
birth. As a result vancomycin clearance rates may increase
considerably during a short period of time. Dose adjust-
ments based on initial trough serum concentrations
should therefore also take the maturation of renal function
into account.
Conversely, 8 subjects had supra-therapeutic levels of
vancomycin. Most of these subjects were under 33 weeks
of gestational age. In these very young subjects there is a
potential for nephrotoxicity. Unfortunately, our studycould not provide any evidence of nephrotoxicity as
follow-up of serum creatinine was not available in most
subjects. However, the rapid increase in renal function
shortly after birth, may significantly help overcome any
supra-therapeutic levels of vancomycin and hence reduce
the risk of toxicity.
Previous studies have identified age, weight and renal
function as determinants for vancomycin concentrations
[6,12]. In this study, we confirmed the association
between gestational age and initial trough serum con-
centrations of vancomycin. Although our method to
determine correlations between patient differences was
basic and more accurate methods to determine correla-
tions are available, the influence of age on serum
concentrations was statistically significant, but small. It
is remarkable that an association between age and serum
concentrations was still detected, since the currently
used dosing schemes should take the age dependency of
clearance into account. These results therefore suggest
the current dosing regimen may not be sufficient and
should be modified. We were unable to demonstrate any
significant correlations between initial trough serum
concentrations and weight at start of the therapy, con-
trary to results of other studies [12].
Weight and age are strongly correlated in this popula-
tion, which partly explains the relation of weight and
initial trough serum concentrations in other studies. At
least, our results suggest dosing based solely on weight
may not be adequate to achieve therapeutic levels in
neonates.
It is important to note that the clinical efficacy of
vancomycin in neonates is not only determined by the
trough serum concentration and factors influencing
clearance rates. Clinical efficacy, and thus the therapeutic
range, depends on the MIC of the involved micro-
organism(s), and this may vary among centers or coun-
tries. Reports on therapeutic ranges in one center may not
necessarily reflect therapeutic ranges from another center.
There is a need for individualized therapy, based on
individual MIC-values.
To the best of our knowledge, this is the first study to
correlate MIC-values with initial trough serum concen-
trations. Only 21% of the subjects reached an initial
trough concentration above tenfold the MIC, thus the
vast majority of subjects may have received inadequate
therapy. The best predictor of a clinical outcome of
vancomycin therapy is the AUC/MIC ratio, with an
AUC/MIC value for clinical effect greater than 400 [15].
In clinical practice, it is unfeasible to obtain an AUC,
since serial plasma concentrations are needed for
calculation of the AUC. The trough serum concentra-
tions may be used as another parameter to reflect drug
exposure [16]. The causative CNS spp. in our patients
showed an MIC ≥ 1.5, which is comparable to CNS MIC
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where 93% of coagulase-negative Staphylococci showed
an MIC in the range of 1.0 to 2.0 mg/L [17]. This dem-
onstrates that our CNS spp. can probably be compared
to spp. detected in the surrounding European countries.
Although the use of the E-test may overestimate
MIC-values compared to broth microdilution (as used
by EUCAST) [18,19], it does appear to be more reliable
in predicting treatment response compared to the
EUCAST method [18]. In light of these considerations,
our data may be extrapolated to other comparable
European populations.
Based on the MIC findings in our population and the
MIC-values of the European EUCAST, increasing the
range of the therapeutic trough concentration for vanco-
mycin to 15 – 20 mg/L might well be advisable, not only
in our hospital, but in other centers as well.
In total, 21 out of 112 subjects died, of whom three
subjects died due to an ongoing staphylococcal infection.
These subjects were equally distributed over the sub-,
supra- and therapeutic group. However, due to lack of
information on concurrent morbidities and lack of MIC,
it is impossible to draw conclusions on the association
between sub-therapeutic serum concentrations and mor-
tality in this study. In the first three age categories, 3 out
of 7 patients had sub-therapeutic initial trough serum
concentrations, whereas 1 patient had a supra-therapeutic
initial trough serum concentration. Almost all our patients
were included in the fourth age category, as treatment of
infections with vancomycin in subjects under 7 days of
age is not considered a standard treatment. Thus, consid-
ering the small number of patients in the first three age
categories, our study results can only be applied to pa-
tients with a postnatal age > 7 days, a median gestational
age of 28 weeks (range 24 – 41 weeks) and with a median
birth weight of 890 grams (range 430 – 4140 grams). This
is however the most crucial neonatal class of patients
admitted to a NICU and prone to suffering a central line
sepsis.
Conclusions
In conclusion, we found that the vast majority (47%) of
neonates treated with vancomycin had sub-therapeutic
initial trough serum concentrations. Furthermore, the
observed MIC values indicate that the percentage of
underdosed patients may even be greater. Based on the
MIC data, it may be advisable to raise the lower limit of
the therapeutic range of vancomycin to 15 mg/L for
European neonates with a postnatal age > 7 days, a birth
weight < 1000 grams and gestational age < 28 weeks.
While increasing the therapeutic range will be most cer-
tainly increase the efficacy of vancomycin for the treat-
ment of gram-positive bacteremia, this may also give rise
to a potential increase in toxicity and adverse effects ofvancomycin. Future well-designed (preferably multi-
center) prospective pharmacokinetic and –dynamic
studies should evaluate the association between dosing
schedules, micro-organism profiles and therapy efficacy,
preferably including long term patient outcome. It would
be of patient interest to apply our results by adjusting
the current dosing scheme to allow for more adequate
initial trough serum concentrations in these fragile
patients, at high risk for adverse outcomes.
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